Company Filing History:
Years Active: 2005
Title: Felix Freuler: Innovator in Alzheimer's Research
Introduction
Felix Freuler is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of genetic research, particularly in relation to Alzheimer's Disease. His work focuses on the development of transgenic models that can aid in understanding and treating this complex condition.
Latest Patents
Freuler holds a patent for "Transgenic Drosophila melanogaster expressing a β42 in the eye." This innovative patent describes transgenic flies that exhibit altered phenotypes due to the expression of the Abeta and C99 portions of the human APP gene. The patent also outlines the use of these flies in methods to identify genes and their human homologs that may be involved in Alzheimer's Disease. Furthermore, it discusses the potential of these human homologs as drug targets for developing therapeutics aimed at treating Alzheimer's Disease and other conditions associated with defects in the APP pathway. The patent also includes pharmaceutical compositions comprising substances directed to these genes.
Career Highlights
Freuler is currently associated with Novartis Corporation, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field, enhancing the impact of his research on Alzheimer's Disease.
Collaborations
Some of his notable coworkers include Dalia Cohen and Uwe Jochen Dengler. Their collaborative efforts contribute to advancing research in genetic therapies and drug development.
Conclusion
Felix Freuler's innovative work in the field of Alzheimer's research exemplifies the importance of genetic studies in developing effective treatments. His contributions through patents and collaborations continue to pave the way for advancements in understanding and addressing this challenging disease.